Antithrombotic therapies in patients with prosthetic heart valves: Guidelines translated for the clinician

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 4, 2011, Pages 514-522

  Leiria, Tiago L L ^a   Lopes, Renato D ^b   Williams, Judson B ^b   Katz, Jason N ^c   Kalil, Renato A K ^d   Alexander, John H ^b  

^a INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Bióloga da Companhia Riograndense de Saneamento CORSAN   (Brazil)

Author keywords

Anticoagulation; Guidelines; Heart valves; Vitamin K antagonist; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; CYTOCHROME P450 2C9; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MENADIONE EPOXIDE; PLACEBO; STREPTOKINASE; TECARFARIN; TRIFLUSAL; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; DRUG WITHDRAWAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL RISK; THROMBOEMBOLISM; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM; DRUG ANTAGONISM; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; THROMBOEMBOLISM; VITAMIN K;

EID: 80052306729     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0574-9     Document Type: Article

References (55)

1. Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:948-954
2. Leon MB, Smith CR, Mack M et al (2010) Transcatheter aorticvalve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597-1607
3. Prandoni A (1942) The anticoagulants heparin and the dicoumarin 3,30-methylene-bis-(4-hydroxycoumarin). Bull N Y Acad Med 18:433-458
4. Oliva Berini E, Galan Alvarez P, Pacheco Onrubia AM (2008) Comparison of quality and hemorragic risk of oral anticoagulant therapy using acenocoumarol versus warfarin. Med Clin (Barc) 131:96-97 (Pubitemid 351930543)
5. Jensen CF, Christensen TD, Maegaard M, Hasenkam JM (2009) Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon. J Thromb Thrombolysis 28:276-281
6. Fihn SD, Gadisseur AA, Pasterkamp E et al (2003) Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 90:260-266 (Pubitemid 36992502)
7. Leiria TL, Pellanda L, Miglioranza MH et al (2010) Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic. Arq Bras Cardiol 94:41-45
8. Petersen P, Grind M, Adler J (2003) Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 41:1445-1451 (Pubitemid 36546266)
9. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293 (Pubitemid 40740552)
10. Schwarz UI, Ritchie MD, Bradford Y et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008 (Pubitemid 351347099)
11. Cadamuro J, Dieplinger B, Felder T et al (2010) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 66:253-260
12. Kakar P, Lane D, Lip GY (2006) Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest 130:1296-1299 (Pubitemid 44786718)
13. Kuijer PM, Hutten BA, Prins MN, Buller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457-460 (Pubitemid 29108910)
14. Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423-428 (Pubitemid 26267872)
15. Fang MC, Chang Y, Hylek EM et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745-752
16. Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91-99 (Pubitemid 28405230)
17. Cannegieter SC, Rosendaal FR, Briet E (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635-641 (Pubitemid 24056190)
18. Cannegieter SC, Rosendaal FR, Wintzen AR et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11-17
19. Dasi LP, Simon HA, Sucosky P, Yoganathan AP (2009) Fluid mechanics of artificial heart valves. Clin Exp Pharmacol Physiol 36:225-237
20. ElBardissi AW, DeBardino DJ, Chen FY, Yamashita MH, Cohn LH (2010) Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg 139:1137-1145
21. Baudet EM, Puel V, McBride JT et al (1995) Long-term results of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 109:858-870
22. Bjork VO, Henze A (1975) Management of thrombo-embolism after aortic valve replacement with the Bjork-Shiley tilting disc valve. Medicamental prevention with dicumarol in comparison with dipyridamole-acetylsalicylic acid. Surgical treatment of prosthetic thrombosis. Scand J Thorac Cardiovasc Surg 9:183-191
23. Torn M, Cannegieter SC, Bollen WL et al (2009) Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med 169:1203-1209
24. Acar J, Iung B, Boissel JP et al (1996) AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94:2107-2112 (Pubitemid 26360501)
25. Hering D, Piper C, Bergemann R et al (2005) Thromboembolic and bleeding complications following St. Jude medical valve replacement: results of the German experience with low-intensity anticoagulation study. Chest 127:53-59 (Pubitemid 41724555)
26. Massel D, Little SH (2001) Risks and benefits of adding antiplatelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 37:569-578
27. Larson RJ, Fisher ES (2004) Should aspirin be continued in patients started on warfarin? J Gen Intern Med 19:879-886
28. Turpie AG, Gent M, Laupacis A et al (1993) A comparison of aspirin with placebo in patients treated with warfarin after heartvalve replacement. N Engl J Med 329:524-529 (Pubitemid 23232620)
29. Little SH, Massel DR (2003) Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 4:CD003464
30. Manzano-Fernandez S, Marin F, Pastor-Perez FJ et al (2008) Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 134:559-567
31. Rogacka R, Chieffo A, Michev I et al (2008) Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv 1:56-61 (Pubitemid 351447185)
32. Salem DN, O'Gara PT, Madias C, Pauker SG (2008) Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th edn). Chest 133:593S-629S (Pubitemid 351892973)
33. Vahanian A, Baumgartner H, Bax J et al (2007) Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 28:230-268 (Pubitemid 46276943)
34. Triple Therapy in Patients on Oral Anticoagulation after Drug Eluting Stent Implantation (ISAR-TRIPLE). ClinicalTrials.gov Identifier: NCT00776633. Accessed 14 Jan 2011
35. Schlitt A, Hauroeder B, Buerke M et al (2002) Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Res 107:39-43 (Pubitemid 35291083)
36. McKellar SH, Thompson JL III, Garcia-Rinaldi RF, Macdonald RJ, Sundt TM III, Schaff HV (2008) Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine. J Thorac Cardiovasc Surg 136:908-914
37. Butany J, Ahluwalia MS, Munroe C et al (2003) Mechanical heart valve prostheses: identification and evaluation. Cardiovasc Pathol 12:1-22 (Pubitemid 36206507)
38. Gherli T, Colli A, Fragnito C et al (2004) Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 110:496-500 (Pubitemid 39036177)
39. Colli A, Verhoye JP, Heijmen R et al (2008) Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION registry survey results. Eur J Cardiothorac Surg 33:531-536
40. Colli A, D'Amico R, Mestres CA et al (2010) Is early antithrombotic therapy necessary after tissue mitral valve replacement? J Heart Valve Dis 19:405-411
41. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C (2005) Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 27:854-860 (Pubitemid 40585681)
42. Kearon C, Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506-1511
43. Bonow RO, Carabello BA, Chatterjee K et al (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118:e523-e661
44. Bonow RO, Carabello BA, Kanu C et al (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114:e84-e231 (Pubitemid 44268973)
45. Garcia DA, Regan S, Henault LE et al (2008) Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 168:63-69
46. Wijdicks EF, Schievink WI, Brown RD, Mullany CJ et al (1998) The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 42:769-773 (Pubitemid 28208361)
47. Babikian VL, Kase CS, Pessin MS, Caplan LR, Gorelick PB (1988) Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves. Stroke 19:407-408
48. Roudaut R, Lafitte S, Roudeaut MF et al (2009) Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis 102:269-277
49. Gupta D, Kothari SS, Bahl VK et al (2000) Thrombolytic therapy for prosthetic valve thrombosis: short- and long-term results. Am Heart J 140:906-916
50. Caceres-Loriga FM, Perez-Lopez H, Morlans-Hernandez K et al (2006) Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis 21:185-190
51. Karthikeyan G, Math RS, Mathew N et al (2009) Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation 120:1108-1114
52. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502 (Pubitemid 32758501)
53. Kulik A, Le May M, Wells GA, Mesana TG, Ruel M (2005) The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med 6:15
54. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
55. Sun JC, Davidson MJ, Lamy A, Eikelboom JW (2009) Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374:565-576